Who is sponsoring NCT05670925?

NCT05670925 is sponsored by Fudan University.

What drugs are being tested in NCT05670925?

Interventions in NCT05670925: Camrelizumab plus Famitinib with/without nab-Palitaxel.

What condition does NCT05670925 study?

NCT05670925 studies Triple-Negative Breast Cancer.

Is NCT05670925 still recruiting?

NCT05670925 is currently status unknown. Last updated 28 February 2023.

Last reviewed 2023-02-28 · How we verify

NCT05670925

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Status unknown Phase 2 Last updated 28 February 2023

What this trial tests

Phase 2 trial testing Camrelizumab plus Famitinib with/without nab-Palitaxel in Triple-Negative Breast Cancer in 46 participants. Status unknown.

Timeline

1 March 2023

Primary endpoint
1 September 2023

1 September 2023

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	1 March 2023
Primary completion	1 September 2023
Estimated completion	1 September 2023
Sites	1 location across China

Drugs / interventions tested

Camrelizumab plus Famitinib with/without nab-Palitaxel — full drug profile →

Conditions studied

Triple-Negative Breast Cancer — all drugs for Triple-Negative Breast Cancer →

Sponsor

Fudan University

Who can join

Adults 18 to 70, female only, with Triple-Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is being conducted to evaluate the Opportune Administration of Nab-paclitaxel in the First Line Treatment Strategy, Camrelizumab and Famitinib with/without Nab-paclitaxel, of Patients with Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research.
Pont M, Marqués M, Sorolla A. · · 2024 · cited 18× · PMID 39769279 · DOI 10.3390/ijms252413518
Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review.
Panda VK, Mishra B, Mahapatra S, Swain B, et al · · 2025 · cited 17× · PMID 39858015 · DOI 10.3390/cancers17020234
Immunotherapy and its racial specificity for breast cancer treatment in Asia: a narrative review.
Xu RC, Zhang YW, Liu CC, Xu YY, et al · · 2025 · cited 3× · PMID 40443538 · DOI 10.1016/j.lanwpc.2024.101180

Verify or expand the search:

Other recruiting trials for Triple-Negative Breast Cancer

Currently open trials in the same condition.

NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Pa · NA · recruiting
NCT07104266 — Triple Negative Breast Cancer and Celecoxib. Pilot Study · Phase 2 · recruiting
NCT06393374 — Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) · Phase 3 · recruiting
NCT05806060 — Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer · Phase 3 · recruiting
NCT05760378 — Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or M · Phase 3 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05670925 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 28 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05670925.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing